InvestorsHub Logo
Followers 15
Posts 1189
Boards Moderated 1
Alias Born 12/31/2008

Re: Ned Serious post# 2215

Wednesday, 03/19/2014 9:59:16 AM

Wednesday, March 19, 2014 9:59:16 AM

Post# of 6939
SYN: $3.38 - Price target raised to $6 - I plan on holding through today and waiting for the Pertussis data to come in (hopefully positive) soon. Will probably sell on that spike (if it happens).

link : http://finance.yahoo.com/news/short-story-briefing-com-125001333.html

8:58 am Synthetic Biologics target raised to $6 at Maxim Group following meetings with mgmt

Maxim Group raises its SYN tgt to $6 from $3. Firm concludes that there are now multiple events ahead, including top-line data for Trimesta (oral estriol) in relapsing/remitting multiple sclerosis in April. In addition, SYN-004 (a second-generation product) should progress to the clinic (for the start of a phase 1b/2 trial) for the prevention of C-difficile infection. SYN-005 (mAb) for pertussis (whooping cough) is another catalyst that has shown compelling animal data (whooping cough is an unmet medical need), as well as the development of SYN-010 for C-IBS and related GI disorders and SYN-001 for life-threatening Acinetobacter (gram negative bacterium) infections.

These thoughts are just mine, not right, not wrong, just thoughts. Invest in what you believe in, not what I believe in. Do your research, and invest in the facts.

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.